Committed to provide the experience and expertise you need
Many, if not most contract research organizations, are staffed and equipped to handle most common studies used in pharmaceutical research. However, some drug development programs — especially those on the cutting edge of technology — fall well outside standard study parameters and require experience and expertise not found at every CRO.
CEDRA’s Special Studies Unit is headed by CEDRA Medical Director, Mark Leibowitz, M.D., and is comprised of experienced, board-certified physicians, nurses, psychologists, psychometricians, pharmacists, pharmacokineticists, paramedics and other dedicated staff who can provide 24-hour coverage for these demanding studies.
As principal investigator or investigator on more than 200 studies, Dr. Leibowitz has amassed an exceptional range of experience in many specialized patient studies including obesity, migraine, insomnia, sexual dysfunction, ADHD, gastrointestinal disorders, diabetes, hypertension, HIV and multiple sclerosis. Dr. Leibowitz also has particular expertise in psychotic, affective and anxiety disorders, Parkinson’s Disease and Alzheimer’s Disease.
In addition, CEDRA’s association with parent company Worldwide Clinical Trials means you can also work with some of the world’s most notable researchers, Dr. Neal R. Cutler, Dr. Michael F. Murphy, and Dr. John J. Sramek, to develop and conduct state-of-the-art protocols which address and answer crucial questions about drug effects at an early stage in the development process.
Neal R. Cutler, M.D., is the president and CEO of WCT, and the founder and chairman of the original Worldwide Clinical Trials, Inc., a global CRO. Dr. Cutler has given hundreds of presentations in the areas of aging, clinical pharmacology, and drug development, and has authored over 226 publications including nine books on the topics of clinical pharmacology, aging, Alzheimer’s disease, schizophrenia, anxiety disorders, and diabetes.
Chief Medical and Scientific Officer Michael F. Murphy, M.D., Ph.D., is a faculty member within the Center for Experimental Pharmacology and Therapeutics at Harvard-MIT Division of Health Sciences and Technology. He is board-certified in psychiatry and has a doctorate in pharmacology, with training at Tulane University, Stanford University, and the Mt. Sinai School of Medicine.
John J. Sramek, Pharm. D., WCT director of clinical research, has authored over 210 publications on psychopharmacology and various aspects of clinical pharmacology and drug development, including eleven books and numerous book chapters. Dr. Sramek has also worked on the design and clinical development of nearly 200 compounds over the full range of clinical drug development, from initial human pharmacology through pivotal efficacy trials.